|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated early changes in and effects of EPO on renal tissues of rats with myocardial infarction by morphology and immunohistochemistry.
|
29671622 |
2018 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As CO also increases serum EPO levels in human volunteers, these findings continue to support therapeutic use of CO to treat IRI in association with organ transplantation, stroke, and myocardial infarction.
|
29463714 |
2018 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied 60 Wistar rats divided into the following groups: control (CT), control + EPO (CT + EPO), myocardial infarction + EPO (MI + EPO), and myocardial infarction (MI).
|
29120671 |
2018 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
We assessed the effects of combined polyethylene glycol hydrogel (PEG), human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM), and erythropoietin (EPO) therapy in a rat model of myocardial infarction.
|
28988988 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite the promising preclinical data, large cohort clinical studies in humans failed to show a significant amelioration in cardiac function upon systemic injection of EPO in patients with myocardial infarctions.
|
28629520 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction.
|
21944383 |
2013 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erythropoietin administration after myocardial infarction reduced the area of infarction and hemorrhage.
|
23453036 |
2013 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction.
|
21362129 |
2012 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study is to investigate the protective effects of EPO in porcine MI.
|
22038108 |
2012 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
EPO-alfa (10 IU/mL) was used in vitro and darbepoetin alfa (40 microg/kg/3 weeks, starting 3 weeks after MI) in vivo.
|
20139114 |
2010 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
CTD_human |
The association of intense isometric exercise, abuse of erythropoietin and nandrolone is likely to have predisposed to coronary thrombus formation and acute myocardial infarction, as the patient presented no traditional cardiovascular risk factors.
|
19337937 |
2009 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates for the first time that, despite high hematocrit levels, endogenously overexpressed EPO provides protection against myocardial infarction in a murine model of permanent LAD ligation.
|
17998053 |
2007 |